Abstract
Regorafenib is a standard therapy for patients with unresectable hepatocellular carcinoma (uHCC) after progression on sorafenib. However, there is no known reliable factor predictive of clinical outcomes for regorafenib. Serum alpha-fetoprotein (AFP) was reported as a significant predictive factor for the outcome of patients with advanced HCC on sorafenib treatment. In this multinational retrospective cohort study, implication of serum alpha-fetoprotein (AFP) in the prediction of effectiveness of regorafenib in uHCC was investigated.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
